EMEA-001521-PIP01-13-M04

Key facts

Active substance
Luspatercept
Therapeutic area
Haematology-Hemostaseology
Decision number
P/0024/2020
PIP number
EMEA-001521-PIP01-13-M04
Pharmaceutical form(s)
Powder for solution for injection
Condition(s) / indication(s)
  • Treatment of beta-thalassaemia
  • Treatment of myelodysplastic syndromes
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Celgene Europe B.V.

Tel. +41 327298500
E-mail: medinfo.emea@celgene.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating
Average
1 rating